A Phase 3 Randomized Double-Blind Placebo- and Active-Comparator- Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Melanoma
    Cutaneous Melanoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Has surgically resected and histologically/pathologically confirmed diagnosis of Stage IIB or IIC (pathological or clinical), III, or IV cutaneous melanoma (including acral)
    2. Has not received any prior systemic therapy for their melano

You may not be eligible for this study if the following are true:

    1. Has ocular or mucosal melanoma
    2. Has past or current in-transit metastases or satellitosis
    3. Has clinically significant heart failure, defined as New York Heart Association class III or IV, within the past 6 months, unless the dis


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.